Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb)

Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no wilful infringement: Centocor Ortho Biotech v Abbot Labs (Gray on Claims) (EDTexweblog.com)

WTO Forum – Bypassing international agreements may hamper medicine access (IP Watch)

Protecting regulatory data in the agricultural industry (IP Osgoode)

Brazil: Pharma companies may well end up subsidising Rio 2016 (IAM)

EU raids Sanofi-Aventis, Novartis and Ratiopharm on suspected antitrust abuse (GenericsWeb)

EU: Paediatric extensions: ‘more disharmony’ (The SPC Blog)

US: NIH shocked to find patents work as expected (Patent Baristas)

US: Industry and academia collaboration pitfalls illustrated in CAFC’s decision in Board of Trustees of the Leland Stanford Junior University v Roche Molecular Systems Inc (Patent Docs)

US: Boehringer Ingelheim Pharma files suit seeking review and correction of patent term adjustment calculation for patent covering ‘process for preparing acyclic HCV protease inhibitors’ (Patent Docs)

Actos (Pioglitazone) – US: Supreme Court refuses to hear Mylan’s appeal over Takeda’s attorneys’ fees (Patent Docs)

Adderall XR (Amphetamine, Dextroamphetamine) – US: Shire and Sandoz settle all pending litigation (SmartBrief)

Amrix (Cyclobenzaprine) – US: Court bifurcates infringement and antitrust determinations in Amrix dispute between Mylan and Cephalon (Patent Docs)

Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb)

Antara (Fenfibrate) – US: Lupin acquisition ends Oscient infringement suit (Patent Docs)

Arzzera (Ofatumumab) – US: Glaxo Group seeks declaratory judgment of invalidity and non infringement against Genentech and City of Hope (Patent Docs)

Caduet (Atorvastatin) – US: Pfizer files patent infringement suits against Sandoz in districts of Colorado and Delaware following Para IV challenge (Patent Docs)

Cozaar (Losartan) – Ireland: Grounds for Irish Losartan decision available (SPC blog)

Eloxatin (Oxaliplatin) – US: Federal Court approves Eloxatin settlement agreement between Sanofi Aventis and Sun Pharmaceuticals (Patent Docs)

Evista (Raloxifene), Xigris (Drotrecogin alfa) – US: Ariad v Lilly: Novozme files amicus brief arguing against Lilly written description; talking written description requirement blues – Ariad wobbles (Holman’s Biotech IP Blog) (Patents4Life)

Flomax (Tamsulosin) – US: Impax Laboratories reaches agreement with Astellas Pharma and Boehringer Ingelheim to settle pending litigation for Flomax (SmartBrief) (Patent Docs)

Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no wilful infringement: Centocor Ortho Biotech v Abbot Labs (Gray on Claims) (EDTexweblog.com)

Luvox (Fluvoxamine) – US: Elan files patent infringement suit against Actavis Elizabeth and Anchen following Para IV challenge (Patent Docs)

Plavix (Clopidogrel) – US: Apotex files suit against Sanofi seeking declaratory judgment of uneforceability based on defendants’ failure to report all information to FTC concerning license agreement between the parties (Patent Docs)

Prandin (Repaglinide) – District Court orders patent use code change; Novo Nordisk appeals (FDA Law Blog)

Seasonale (Ethinyl estradiol, Levonorgestrel) – US: Teva files suit against India’s Lupin to keep oral contraceptive monopoly (IP Factor) (Patent Docs) (America-Israel Patent Law)